ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 16 of 405 for:    Recruiting, Not yet recruiting, Available Studies | "Tissue Donors"

Effects of Dexmedetomidine on Delirium After Living Donor Renal Transplantation in Adult Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02509949
Recruitment Status : Recruiting
First Posted : July 28, 2015
Last Update Posted : June 12, 2018
Sponsor:
Information provided by (Responsible Party):
Tao Zhang, First Affiliated Hospital, Sun Yat-Sen University

Brief Summary:

Delirium, an acute change in mental status, is a serious medical complication among hospitalized patients. Syndrome of delirium involves agitation, sleep disturbance, affective disorders and cognitive disruptions.

One vulnerable period for developing delirium is in the postoperative days. Postoperative delirium often initiates a cascade of adverse consequences including an increase in length of stay and hospital costs, and greater mortality. The investigators have observed that the incidence of postoperative delirium in patients after renal transplantation is about 20-30% in our hospital.

Several studies have revealed that dexmedetomidine, as a widely used sedative during anesthesia, can decrease the incidence of postoperative delirium after cardiac surgery. The investigators aim to examine whether administration of dexmedetomidine can reduce postoperative delirium after living donor renal transplantation in adult patients.


Condition or disease Intervention/treatment Phase
Postoperative Delirium After Living Donor Renal Transplantation Drug: Dexmedetomidine Drug: Saline Phase 4

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Outcomes Assessor)
Primary Purpose: Prevention
Study Start Date : May 2015
Estimated Primary Completion Date : September 2019

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Dexmedetomidine
Dexmedetomidine ivpump 0.2ug/kg/h during living donor renal transplantation.
Drug: Dexmedetomidine
Placebo Comparator: Saline
Saline ivpump 0.2ug/kg/h during living donor renal transplantation.
Drug: Saline



Primary Outcome Measures :
  1. Postoperative Delirium [ Time Frame: Postoperative day 1-7. ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 59 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • age > 17 and < 60 years;
  • American Society of Anesthesiology (ASA) I-III;
  • admitted for living donor renal transplantation.

Exclusion Criteria:

  • Patients with a history of drug abuse;
  • preoperative history of schizophrenia, epilepsy, parkinsonism, use of cholinesterase inhibitor, inability to communicate in the preoperative period (coma, profound dementia, or language barrier).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02509949


Locations
China, Guangdong
First Affiliated Hospital, Sun Yat-Sen University Recruiting
Guangzhou, Guangdong, China, 510080
Contact: Tao Zhang, Master of Medicine    13580482938    zhtao98@aliyun.com   
Sponsors and Collaborators
Tao Zhang

Responsible Party: Tao Zhang, First Affiliated Hospital, Sun Yat-Sen University
ClinicalTrials.gov Identifier: NCT02509949     History of Changes
Other Study ID Numbers: DDRT
First Posted: July 28, 2015    Key Record Dates
Last Update Posted: June 12, 2018
Last Verified: June 2018

Additional relevant MeSH terms:
Delirium
Confusion
Neurobehavioral Manifestations
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms
Neurocognitive Disorders
Mental Disorders
Dexmedetomidine
Hypnotics and Sedatives
Central Nervous System Depressants
Physiological Effects of Drugs
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Adrenergic alpha-2 Receptor Agonists
Adrenergic alpha-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action